Patents by Inventor John Mancuso

John Mancuso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20260159528
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 11, 2026
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Bhaumik PANDYA, Alan P. KAPLAN, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • Fused imidazole derivatives as AHR antagonists
    Patent number: 12570638
    Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: March 10, 2026
    Assignee: Sail Biomedicines, Inc.
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20250304580
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: February 25, 2025
    Publication date: October 2, 2025
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Bhaumik PANDYA, Alan P. KAPLAN, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 12428425
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: September 21, 2023
    Date of Patent: September 30, 2025
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20250042897
    Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
    Type: Application
    Filed: November 9, 2022
    Publication date: February 6, 2025
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Bhaumik PANDYA, Alan P. KAPLAN, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20240309003
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: May 4, 2022
    Publication date: September 19, 2024
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Maxence BOS, John MANCUSO, Ivan FRANZONI, Bhaumik PANDYA, Alan KAPLAN
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20240182477
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: September 21, 2023
    Publication date: June 6, 2024
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11912711
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: February 27, 2024
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11884675
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: January 30, 2024
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • Fused Imidazole Derivatives as AHR Antagonists
    Publication number: 20230331705
    Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 19, 2021
    Publication date: October 19, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20230295170
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: November 30, 2022
    Publication date: September 21, 2023
    Inventors: Lara C. CZABANIUK, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20230295169
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: November 30, 2022
    Publication date: September 21, 2023
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS
    Publication number: 20230295152
    Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.
    Type: Application
    Filed: November 20, 2020
    Publication date: September 21, 2023
    Applicant: SENDA BIOSCIENCES, INC.
    Inventors: Alessandra BARTOLOZZI, John Robert PROUDFOOT, Timothy BRIGGS, John MANCUSO, Karunakar Reddy BONEPALLY, Patrick BUREAU, Tianlin GUO, Maxence BOS, Anna BLOIS, Bernard LANTER, Steven John TAYLOR, Leonard BUCKBINDER, Francesca BARONE
  • Fused Azole Heterocycles as AHR Antagonists
    Publication number: 20230234967
    Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 27, 2021
    Publication date: July 27, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Tianlin Guo, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
    Patent number: 11608344
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 21, 2023
    Assignees: AMGEN INC., VIGIL NEUROSCIENCE, INC.
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20230002390
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 5, 2023
    Inventors: Lara C. CZABANIUK, Timothy HOPPER, Jonathan B. HOUZE, Jane PANTELEEV, Gwenaella RESCOURIO, Vincent SANTORA, Haoxuan WANG, Ryan D. WHITE, Alice R. WONG, Yongwei WU, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • SOLID PHASE SYNTHESIS OF CYCLIC AMINO ACID MOLECULES
    Publication number: 20170320908
    Abstract: The present invention relates to cyclic amino acid molecules and methods of preparing the same, and in particular the macrocyclization of amino acids or linear peptides bound to a solid support.
    Type: Application
    Filed: November 17, 2015
    Publication date: November 9, 2017
    Inventors: Jennifer L. Hickey, John Mancuso, Eric Marsault, Andrew L. Roughton, Adam P. Treder, Marie-Claude J. Trembley, Andrei K. Yudin, Serge Zaretsky
  • Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors
    Publication number: 20160222026
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
    Type: Application
    Filed: September 14, 2015
    Publication date: August 4, 2016
    Inventors: Robert Deziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
  • Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
    Patent number: 9193749
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: November 24, 2015
    Assignees: Forum Pharmaceuticals, Inc., MethylGene, Inc.
    Inventors: Robert Deziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
  • Inhibitors of histone deacetylase
    Patent number: 8673911
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: March 18, 2014
    Assignee: MethylGene Inc.
    Inventors: Tammy Mallais, Oscar Moradei, Alain Ajamian, Pierre Tessier, David Smil, Sylvie Frechette, Silvana Leit, Patrick Beaulieu, Robert Deziel, John Mancuso